Comparison of quality of life between docetaxel and weekly paclitaxel in the neoadjuvant or adjuvant treatment of breast cancer
Oncology · 2026-11-09
DOI: 10.1159/ocl/aebag013 ↗Abstract
Abstract Introduction: Taxane-based chemotherapy remains a cornerstone of neoadjuvant and adjuvant treatment for stage II–III breast cancer. Weekly paclitaxel and 3-weekly docetaxel exhibit comparable oncologic efficacy but differ in toxicity profiles and treatment schedules. This study aimed to compare longitudinal patient-reported quality-of-life (QoL) outcomes between these two taxane regimens. Methods: This single-center observational cohort study included 82 patients with stage II–III breast cancer who received anthracycline-based chemotherapy followed by either docetaxel every 3 weeks (n=55) or weekly paclitaxel (n=27). QoL was assessed at four time points using the Functional Assessment of Cancer Therapy–Breast (FACT-B), Beck Anxiety Inventory, Beck Depression Inventory, Pittsburgh Sleep Quality Index, and Quality of Life Enjoyment and Satisfaction Questionnaire. Longitudinal changes and between-group differences were also analyzed. Results: Baseline QoL scores were comparable between groups. During active treatment, both regimens were associated with deterioration in several QoL domains, with recovery observed following treatment completion. At the third assessment time point, corresponding to peak treatment burden, patients receiving docetaxel reported significantly higher depressive symptoms and lower life satisfaction compared with those receiving weekly paclitaxel. However, global FACT-B scores or sleep quality showed no significant differences at any time point. Hematologic adverse events, particularly anemia and neutropenia, were more frequent in the docetaxel group, whereas peripheral sensory neuropathy was more common with weekly paclitaxel. No grade 4 adverse events or treatment-related deaths occurred. Conclusions: Weekly paclitaxel and 3-weekly docetaxel yielded broadly comparable longitudinal QoL outcomes in curative-intent breast cancer treatment. Docetaxel was associated with a greater short-term psychological burden during peak chemotherapy exposure. These findings highlight the importance of incorporating patient-reported outcomes into treatment selection and supportive care strategies.
EUVIMED